Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?

WENDLING DANIEL, VINCENT DI MARTINO and GEORGES HERBEIN
The Journal of Rheumatology June 2009, 36 (6) 1107-1108; DOI: https://doi.org/10.3899/jrheum.090119
WENDLING DANIEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dwendling@chu-besancon.fr
VINCENT DI MARTINO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGES HERBEIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Biologic agents have increased the therapeutic armamentarium against immune-mediated disorders, and particularly rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Nevertheless, infectious side effects are a major concern in the use of these biologics, especially anti-tumor necrosis factor (TNF) agents1. In this context, the use of TNF blockers in patients with chronic viral infection seems hazardous, and represents an unresolved issue2.

In this issue of The Journal, Zingarelli, et al3 report 3 cases of patients with RA positive for HBsAg, in which anti-TNF therapies (etanercept, infliximab then etanercept, adalimumab) under prophylactic use of lamivudine were not associated with hepatitis reactivation, even after anti-TNF discontinuation with prolonged lamivudine therapy.

In one of their cases, an increase in HBV viral load occurred after discontinuation of methotrexate. Methotrexate was reported to induce subfulminant hepatitis B virus reactivation after its withdrawal4,5. This illustrates the interactions of the underlying condition and the associated immunosuppressive therapy that may confuse our interpretation of the responsibility of the biologic agent in viral reactivation.

Irrespective of chronic viral infection, anti-TNF agents may induce immune-mediated hepatitis6, with different risk between chimeric antibody and soluble receptor. Although uncommon, this possibility should be kept in mind and ruled out in case of acute hepatitis occurring under TNF blockers.

Anti-TNF should be used with great caution in patients with chronic hepatitis B7. Only a few reports are available describing such a situation, as emphasized by Zingarelli, et al3, sometimes due to an incomplete screening before starting anti-TNF therapy. This reactivation may occur whatever currently available anti-TNF agent is used, illustrating a class effect of these agents, and the implication of TNF-α and its receptors in the immune-mediated control of viral replication8.

It may be important to account for the underlying disease. In RA, there are currently alternative biologic therapeutic options to TNF blockers, but this is not the case in other conditions such as AS. We recently encountered 4 cases of HBsAg-positive patients with AS treated with anti-TNF agents9. In 2 cases, HBsAg positivity was a finding of the pretherapeutic screening; in the 2 other cases, chronic viral infection was known before the rheumatic disease began. In 2 cases, lamivudine treatment was initiated after a short-term reactivation (increase in viral load), and in 2 cases antiviral therapy was concomitant to initiation of anti-TNF, with control of the viral disease for a 12–48 month followup. We agree with Zingarelli, et al3 about the interest of longterm followup of these patients, even after withdrawal of anti-TNF therapy. Because of their potent antiviral activity associated with a high barrier to resistance, entecavir and tenofovir are the first-line antiviral therapies now recommended in chronic hepatitis B10. However, the majority of HBV reactivations associated with anti-TNF reported to date were controlled by lamivudine, the first available nucleoside analog efficient against HBV. The literature review in the article by Zingarelli, et al3 shows that lamivudine was efficacious if initiated before anti-TNF treatment or in the case of hepatitis reactivation. Nevertheless, acquired resistance commonly occurred after several months of lamivudine therapy11, as in one of our cases9 after 42 months and 3 successive anti-TNF agents. The addition of a second antiviral agent (adefovir) despite ongoing anti-TNF therapy led to the subsequent control of viral load in our case. Recently, a HBsAg-positive patient with RA receiving tocilizumab (anti-interleukin 6 receptor antibody) for more than 5 years along with entecavir was reported to have no exacerbation of hepatitis12. All these cases emphasize the need for tight followup of HBV viral load in HbsAg-positive patients receiving anti-TNF, and biologic treatment in general.

See Use of TNF-α-blocking agents in HBV-positive patients, page 1188

Surprisingly, few cases of HBsAg-positive carriers treated with anti-TNF without antiviral therapy did not experience HBV reactivation over a 12 month followup period13. Conversely, HBV reactivation under anti-TNF has been reported in some HBsAg-negative, HBc and HBs antibody-positive patients, suggesting that occult HBV infection may be exacerbated by anti-TNF14. Such an event, however, seems uncommon: preliminary results of 34 month followup of 21 HBsAg-negative, HBc and HBs antibody-positive patients with inflammatory rheumatism pattern treated by TNF therapy showed no HBV reactivation15.

Viral reactivations under anti-TNF are not restricted to HBV16 or rheumatologic illness3. HBV reactivation under rituximab has been demonstrated, despite antiviral therapy, in hematological conditions17,18, as well as in AS19. A retrospective study20 reported 64 cases of viral infection in patients receiving rituximab to treat lymphoma; the infection was mainly due to HBV (39%), cytomegalovirus (23%), and varicella zoster virus (9%).

An expert group of the French Society for Rheumatology recommends serological testing for HBV before starting rituximab. In case of HBV infection, advice from a hepatologist must be obtained before making treatment decisions21.

Obviously, the situation is not unequivocal, and practical guidelines based upon case records as proposed in the article3 are useful for current practice, since prospective randomized studies in these at-risk patients would probably not be performed.

Footnotes

REFERENCES

  1. 1.↵
    1. Patkar NM,
    2. Teng GG,
    3. Curtis JR,
    4. et al
    . Association of infections and tuberculosis with anti-tumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008;20:320–6.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wendling D,
    2. Herbein G
    . TNF-alpha antagonist therapy in patients with joint disease and chronic viral infection. Joint Bone Spine 2007;74:407–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Zingarelli S,
    2. Frassi M,
    3. Bazzani C,
    4. et al
    . Use of tumor necrosis alpha-blocking agents use in hepatitis B virus-positive patients. Reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188–94.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Narvaez J,
    2. Rodriguez-Moreno J,
    3. Martinez-Aguila MD,
    4. Clavaguera MT
    . Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998;25:2037–8.
    OpenUrlPubMed
  5. 5.↵
    1. Ito S,
    2. Nakazono K,
    3. Murazawa A,
    4. et al
    . Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339–42.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Thiefin G,
    2. Morelet A,
    3. Heurgué A,
    4. et al
    . Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept. Joint Bone Spine 2008;75:737–9.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pham T,
    2. Claudepierre P,
    3. Deprez X,
    4. et al.,
    5. Club Rhumatismes et Inflammation, French Society of Rheumatology
    . Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005;72 Suppl 1:S1–58.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Herbein G,
    2. O’Brien WA
    . Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241–57.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Wendling D,
    2. Di Martino V,
    3. Prati C,
    4. et al
    . Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine; doi:10.1016/j.jbspin.2008.
  10. 10.↵
    1. European Association for the Study of the Liver
    . EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Benhamou Y,
    2. Bochet M,
    3. Thibault V,
    4. et al
    . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302–6.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Nagashima T,
    2. Minota S
    . Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47:1838–40.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Cansu DU,
    2. Kalifoglu T,
    3. Korkmaz C
    . Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421–4.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Montiel PM,
    2. Solis JA,
    3. Chirinos JA,
    4. et al
    . Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718–20.
    OpenUrlPubMed
  15. 15.↵
    1. Charpin CH,
    2. Guis S,
    3. Colson P,
    4. et al
    . A monitoring of patients with hepatitis B serological pattern indicating past infection and treated by TNF α inhibitor for inflammatory rheumatism: preliminary results [abstract]. Arthritis Rheum 2008;58 Suppl:S558.
    OpenUrl
  16. 16.↵
    1. Wendling D,
    2. Streit G,
    3. Toussirot E,
    4. Prati C
    . Herpes zoster during anti TNF treated chronic artrhitis. Joint Bone Spine 2008;75:540–3.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Khaled Y,
    2. Hanbali A
    . Hepatitis B virus reactivation in a case of Waldenstrom’s macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. Am J Hematol 2007;82:688.
    OpenUrlPubMed
  18. 18.↵
    1. Yang SH,
    2. Kuo SH
    . Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008;87:325–7.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Rodriguez-Escalera C,
    2. Fernández-Nebro A
    . The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology 2008;47:1732–3.
    OpenUrlFREE Full Text
  20. 20.↵
    1. Aksoy S,
    2. Harputuoglu H,
    3. Kilickap S,
    4. et al
    . Rituximab related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307–12.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Pham T,
    2. Fautrel B,
    3. Gottenberg JE,
    4. et al.,
    5. Rheumatic Diseases and Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR)
    . Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008;75 Suppl 1:S1–99.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 6
1 Jun 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?
WENDLING DANIEL, VINCENT DI MARTINO, GEORGES HERBEIN
The Journal of Rheumatology Jun 2009, 36 (6) 1107-1108; DOI: 10.3899/jrheum.090119

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Biologic Agents in the Treatment of Rheumatic Diseases with Chronic Viral Infection. Where Are We?
WENDLING DANIEL, VINCENT DI MARTINO, GEORGES HERBEIN
The Journal of Rheumatology Jun 2009, 36 (6) 1107-1108; DOI: 10.3899/jrheum.090119
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Sex Effect in Psoriatic Arthritis
  • Microdissecting Epigenetic Pathways in Oligoarticular Juvenile Idiopathic Arthritis: A New Avenue in Transforming Growth Factor β?
  • Ro52, Myositis, and Interstitial Lung Disease
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire